Quick answer: KLOW is a multi-peptide research blend supplied as a single 80 mg lyophilized vial. It is the generic industry KLOW formulation and combines four components: GHK-Cu, KPV, BPC-157, and TB-500. Read another way, it is the two peptides of the Wolverine Blend (BPC-157 and TB-500) together with the copper tripeptide GHK-Cu and the anti-inflammatory tripeptide KPV. Each component has its own separate research literature. None of the individual components or their combinations are FDA-approved in this formulation, and Velora supplies KLOW for in vitro, ex vivo, and in silico research only.
Research use only: what this article is, and what it isn’t
This is a compound-education reference on the KLOW research blend. It explains what the four components are and what published research has reported about each. It is not medical advice, not a treatment or self-administration guide, and not a document about any human, veterinary, or cosmetic use.
None of the components of KLOW is approved by the U.S. Food and Drug Administration in the formulation Velora supplies. Velora Research supplies the blend as research-grade material sold strictly for in vitro, ex vivo, and in silico laboratory research, not for human consumption, veterinary use, in vivo use in any species, or any personal, wellness, nutritional, or cosmetic application. The research described below is drawn from published preclinical and in-vitro studies of each individual component and is reported here for research orientation only. Nothing about the blend or its components is claimed to produce any specific outcome in humans, animals, or therapeutic applications. Researchers are responsible for compliance with applicable law, including the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 331, § 355, § 360bbb-3), and institutional review requirements.
What KLOW is?
KLOW is the generic, standard-formulation version of a four-peptide research blend, supplied in a single 80 mg lyophilized vial. Velora does not compound a house-specific version; the vial contains the common industry blend of GHK-Cu, KPV, BPC-157, and TB-500. A useful way to place it is against Velora’s other blends: the GLOW blend is GHK-Cu plus the Wolverine Blend (BPC-157 and TB-500), and KLOW is that same trio with the anti-inflammatory tripeptide KPV added. Co-formulating the four holds their ratio constant so a protocol that calls for all of them can be prepared from one reconstitution.
The four components
Each component of KLOW comes from a different area of the peptide literature.
GHK-Cu
GHK-Cu is the copper-bound form of the tripeptide glycyl-L-histidyl-L-lysine. In cell-culture and preclinical models it has been studied across copper-transport chemistry, antioxidant and reactive-oxygen-species pathways, collagen and extracellular-matrix research, and gene-expression profiling of repair-related gene clusters (Pickart & Margolina, *International Journal of Molecular Sciences*, 2018). It is also the reason a blend containing it carries a blue tint and needs protection from light.
KPV
KPV is a tripeptide, lysine-proline-valine, corresponding to the C-terminal sequence of alpha-melanocyte-stimulating hormone (alpha-MSH). It is studied primarily as an anti-inflammatory peptide, and the biochemistry and preclinical anti-inflammatory effects of alpha-MSH and its C-terminal tripeptide are reviewed in detail by Brzoska and colleagues (Brzoska et al., *Endocrine Reviews*, 2008).
BPC-157
BPC-157 is a synthetic 15-amino-acid peptide derived from a partial sequence of a protein found in gastric juice. Published preclinical research has examined it across growth-factor, nitric-oxide, and angiogenesis pathways in animal and in-vitro models (Sikiric et al., *Current Pharmaceutical Design*, 2018).
TB-500
TB-500 is a synthetic peptide derived from the actin-binding region of thymosin beta-4, characterized in the literature as an actin-modulating peptide associated with cell-migration and angiogenesis research (Goldstein et al., *Expert Opinion on Biological Therapy*, 2012).
A note on the cited literature. The references above describe each individual component. They are background on what each molecule is and where it has been studied, not evidence about the behavior of the assembled KLOW blend, which would have to be evaluated on its own. In particular, thymosin beta-4 literature describes the molecular family and is not the same as evidence characterizing a specific commercial TB-500 material.
Why the four are combined?
KLOW is supplied to support multi-pathway research designs that call for all four components together at a fixed ratio. Co-formulating them holds that ratio constant and removes the variance of reconstituting four separate vials, which reduces one potential source of preparation variability across runs. Because Velora supplies the generic blend rather than a compounded house version, the components are the standard four, and the exact per-component amounts for any vial come from that lot’s Certificate of Analysis.
Composition and the COA
KLOW is supplied as a single 80 mg lyophilized vial containing GHK-Cu, KPV, BPC-157, and TB-500. Velora states that each component is independently tested by a third-party analytical laboratory, using HPLC for purity and mass spectrometry for identity. Confirm the per-component amounts and ratio for your specific lot against the active COA, which is the primary lot-specific source for reported composition and analytical results.
Reconstitution and concentration
The information in this section is general laboratory-handling context, not a use protocol. Follow your own institution’s validated standard operating procedures and the product documentation for any specific step.
KLOW ships as an 80 mg lyophilized vial, reconstituted with bacteriostatic water. Because the per-component split is confirmed on the COA, the table below gives the combined concentration; derive each component’s concentration from the amounts stated on the active COA.
| Diluent volume added | Combined concentration (mg/mL) |
| 4.0 mL | 20.0 |
| 5.0 mL | 16.0 |
| 8.0 mL | 10.0 |
As a general handling practice, add the diluent slowly down the inner glass wall and mix by gentle swirling rather than shaking. The four components span a wide size range, from the small GHK-Cu and KPV tripeptides to the larger BPC-157 and TB-500, so per-component molar concentrations differ substantially at any single combined weight. Compute each from its own molecular weight on the COA rather than from the combined figure.
Storage
Store the lyophilized vial sealed at -20°C in a dry, dark place, and let it equilibrate to room temperature before opening. Protect it from light with particular care, because the GHK-Cu component is documented as light-sensitive. Once reconstituted with bacteriostatic water, refrigerate the working stock at 2 to 8°C, protect it from light, and avoid repeat freeze-thaw cycles, which can degrade peptide integrity. Velora has not published a reconstituted stability window for KLOW, so take the usable timeframe from your protocol and the batch COA. The general logic is in the peptide storage guide.
“A four-component blend like this one is where a Certificate of Analysis earns its keep, and I would read the active COA line by line before designing an experiment around KLOW. I want identity by mass spectrometry and purity by HPLC for each component independently, and I pay special attention to the GHK-Cu, because the copper complex is light-sensitive, and its handling shows up in the data. The component literature tells me what each molecule is. The COA tells me what is in the vial in front of me, and at what ratio.” Clark Jones, PhD, Velora Research
Working with verified material
Velora Research supplies the KLOW peptide blend as an 80 mg lyophilized vial, and Velora states each component is independently HPLC- and mass-spec-verified, with a Certificate of Analysis tied to the lot number and published through its Certificates of Analysis hub. Those are Velora’s product-specific representations; confirm the specifics for your lot on its COA. The individual peptides also appear elsewhere in the catalog, as GHK-Cu and the Wolverine Blend, and the same release protocol applies across the full research peptide catalog. For a multi-component blend, the COA is not a formality; it is how you confirm what you are actually studying.
Frequently asked questions
What is the KLOW peptide blend?
KLOW is a multi-peptide research blend in a single 80 mg lyophilized vial. It is the generic industry formulation and contains GHK-Cu, KPV, BPC-157, and TB-500. Velora supplies it for in vitro, ex vivo, and in silico research use only.
What is in KLOW?
Four components: the copper tripeptide GHK-Cu, the anti-inflammatory tripeptide KPV, and BPC-157 plus TB-500 (the two peptides of the Wolverine Blend). Confirm the per-component amounts and ratio for your vial on the active Certificate of Analysis.
How does KLOW relate to GLOW?
GLOW is GHK-Cu plus BPC-157 and TB-500. KLOW is that same trio with the anti-inflammatory tripeptide KPV added, for a four-component blend.
How is the KLOW blend verified?
Each component is independently tested by a third-party analytical laboratory using HPLC for purity and mass spectrometry for identity, with a Certificate of Analysis tied to the lot number.
Is KLOW FDA-approved?
No. None of the components is approved by the FDA in this formulation. KLOW is research-grade material for in vitro, ex vivo, and in silico laboratory use only, not for human or veterinary use.
Sources and further reading
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences. 2018;19(7):1987. PubMed
- Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocrine Reviews. 2008;29(5):581-602. PubMed
- Sikiric P, Rucman R, Turkovic B, et al. Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Current Pharmaceutical Design. 2018;24(18):1990-2001. PubMed
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy. 2012;12(1):37-51. PubMed
About the author
Clark Jones, PhD is a pharmaceutical scientist and medical writer with expertise in molecular biology, oncology, and chemistry. He has worked in the fields of oncology research, regenerative medicine, and pharmaceutical quality control. He has extensive experience with peptide formulations and development in research. In his work, he translates complex scientific literature into evidence-based content while maintaining regulatory and scientific integrity.
ORCID 0009-0005-9356-0297 · LinkedIn · More articles by Clark Jones
